Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris.

What Researchers Did

Researchers investigated if adding hyperbaric oxygen therapy to percutaneous coronary intervention could reduce clinical restenosis.

What They Found

At 8 months, major adverse cardiac events occurred in only 1 of 24 patients (4%) who received hyperbaric oxygen therapy. This was significantly lower compared to 13 of 37 patients (35%) who did not receive the therapy.

What This Means for Canadian Patients

This study suggests that hyperbaric oxygen therapy might be a beneficial adjunct to standard percutaneous coronary intervention for Canadian patients. If proven in larger trials, it could potentially reduce the risk of future cardiac events after these procedures.

Canadian Relevance

This study has no direct Canadian connection.

Study Limitations

A significant limitation of this study is its small sample size, which may limit the generalizability of the findings.